IL13RA2 anticorps

N° du produit ABIN1383686

Il existe 8+ publications pour ce produit. L’anticorps anti-IL13RA2 Monoclonal Souris est utilisé pour la détection de IL13RA2 dans des échantillons de Humain. Il a été validé pour ELISA, IHC et FACS.

Aperçu rapide pour IL13RA2 anticorps (ABIN1383686)

Antigène: IL13RA2 (Interleukin 13 Receptor, alpha 2 (IL13RA2))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp IL13RA2 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)

Clone: B-D13

Détail du produit anti-IL13RA2 anticorps

Specificité: Recognises the IL-13 receptor a2 (IL-13 Ra2), a 44 kDa protein

Purification: Ion exchange chromatography

Stérilité: 0.22 μm filtered

Immunogène: IL-13Ra2 transfected CHO cell line,Myeloma X63/AG.8653 x Balb/c spleen cells

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Phosphate-buffered saline. Sterile-filtered through 0.22 μm. Carrier and preservative free

Agent conservateur: Without preservative

Stock: 4 °C

Stockage commentaire: Stable at +2-8°C for 12 months. For longer storage freeze aliquots.

Références pour anticorps anti-IL13RA2 (ABIN1383686)

Kawakami, Terabe, Kioi, Berzofsky, Puri: "Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 15, pp. 4678-86, (2006) (PubMed).

Kawakami, Kawakami, Puri: "Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease." dans: Molecular cancer therapeutics, Vol. 3, Issue 2, pp. 137-47, (2004) (PubMed).

Blanchard, Durual, Estienne, Bouzakri, Heim, Blin, Cuber: "IL-4 and IL-13 up-regulate intestinal trefoil factor expression: requirement for STAT6 and de novo protein synthesis." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 172, Issue 6, pp. 3775-83, (2004) (PubMed).

Kawakami, Kawakami, Kasperbauer, Hinkley, Tsukuda, Strome, Puri: "Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 9, Issue 17, pp. 6381-8, (2003) (PubMed).

Joshi, Kawakami, Leland, Puri: "Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 8, Issue 6, pp. 1948-56, (2002) (PubMed).

Lordan, Bucchieri, Richter, Konstantinidis, Holloway, Thornber, Puddicombe, Buchanan, Wilson, Djukanović, Holgate, Davies: "Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 169, Issue 1, pp. 407-14, (2002) (PubMed).

Kawakami, Kawakami, Puri: "IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 169, Issue 12, pp. 7119-26, (2002) (PubMed).

Joshi, Plautz, Puri: "Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas." dans: Cancer research, Vol. 60, Issue 5, pp. 1168-72, (2000) (PubMed).

Détails sur IL13RA2

Antigène: IL13RA2 (Interleukin 13 Receptor, alpha 2 (IL13RA2))

Autre désignation: CD213a2

Sujet: IL-13Ra2

Poids moléculaire: 74 kDa